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Dincluded in this substudy also had scar on the anterior
wall.Study Limitations
In this study, SPECT imaging was the only modality used
for assessing myocardial viability. Other commonly used
tests (eg, delayed enhancement cardiac magnetic resonance
imaging) have not been examined in the STICH trial. It is
possible that the more detailed and quantitative myocardial
scarring information provided by delayed enhancement
imaging with magnetic resonance would prove useful in
the selection of appropriate patients for SVR. This possibil-
ity deserves further investigation.
The SVR hypothesis of the STICH trial was not designed
to examine the impact of viability determination on
outcomes in these patients. The present observations are
based on a post hoc analysis of a subset of STICH patients
who underwent viability testing with SPECT. Thus, the
impact of these observations is reduced compared with a
trial specifically designed to address this issue. In addition,
the reduced number of patients limits the statistical power
of our findings. Finally, the decision to enroll patients in
this trial could have been influenced by prior viability
testing. However, it must be noted that the majority of
patients in this report had viability testing performed after
randomization.CONCLUSIONS
In patients with CAD and severe regional LV
dysfunction, assessment of myocardial viability does not
identify patients who will benefit in terms of survival
from adding SVR to CABG.EDITORIAL CO
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Cardiol. 2004;44:1439-45.MMENTARYSurgical ventricular restoration, myocardial viability, and your mother’s
fine chinaJohn M. Toole, MDSee related article on pages 2677-84.Holly and colleagues1 present a post hoc analysis of the sur-
gical arm of the Surgical Treatment for Ischemic Heart Fail-
ure (STICH) trial with hopes of shedding light on whether
the presence or absence of myocardial viability alters out-
comes after coronary artery bypass grafting (CABG) and
surgical ventricular reconstruction (SVR) compared with




Dthat remain valid in this post hoc analysis. In addition, anal-
ysis of a randomized trial based on variables not included in
the original randomization process introduces clinical bias
and weakens the results. This is evident in this study
because only 267 patients of the 1000 undergoing surgery
in the STICH had viability data. Nonetheless, it is intuitive
that CABG alonewould yield significant benefits in patients
with septal and apical viability, and that addition of SVR
might be harmful in these patients. Conversely, CABG/
SVR might selectively benefit those with nonviable
myocardium to be excluded by SVR.
Recruitment into any arm of the STICH trail required pa-
tients to be a candidate for medical management or CABG
with or without SVR.2 This excluded patients with left main
disease, severe or unstable angina, and acute coronary syn-
dromes. It also excluded patients with apical aneurysms and
no need for surgical coronary intervention. Dor and col-
leagues3 nicely illustrated a large series of patients who
met exclusion criteria for STICH enrollment but, in their
hands, achieved excellent clinical results after SVR with
or without CABG. Of note, ventricular volumes in this se-
ries were large and average end-systolic volume index
was reduced by approximately 50%. Reflecting trends at
the time, the STICH trial included modestly enlarged ven-
tricles and realized an average reduction of only 19% in
end-systolic volume index.Many surgeons think the STICH
trial reflects the results of inappropriate or overuse of SVR
(the so-called drive-by SVR). Others argue that this was a
trial of the procedure as it had evolved to be applied and
therefore highly relevant. The results of the STICH trial
should not be blindly extrapolated to all patients but rather
applied to those meeting inclusion criteria.
In a similar post hoc analysis of the STICH trial, Bonow
and colleagues4 found that therewas no difference in survival
based on myocardial viability (as determined by single
photon computed tomography or dobutamine stress echocar-
diography) once risk factors had been taken into account.
Unlike the current study, this analysis included medically
managed patients and was not designed to examine the ef-
fects of SVR based onviability. The current analysis attempts
to address just that and answer the question from a more
practical and surgical perspective. In this study, viabilityThe Journal of Thoracic and Carwas not found to alter postoperative mortality when analyzed
globally or regionally in patients undergoing CABG.
This study is subject to the debatable design problems
with the STICH trial and inherent weaknesses of a post
hoc analysis of a prospective randomized trial. Although it
may not reflect the results achieved by Dor and colleagues3
on larger ventricles, there are strengths to this study. It was
prospective, used core laboratories for echocardiography
and single photon computed tomography analysis, and,
with 267 patients, may be the most accurate assessment of
the importance of myocardial viability in the setting of
SVR available. Ultimately, the take home message from
the STICH trial is SVR should not be casually added to
CABG in patients with normal tomoderately enlarged hearts
and apical wall motion abnormalities. Accordingly, use of
SVR seems to have decreased significantly since the STICH
trial. This study suggests that even those with nonviable
myocardium do not benefit from the addition of SVR to
CABG. This does not mean we should throw the baby out
with the bathwater and abandon SVR. SVR is a physiologi-
cally attractive procedure but, in many ways, is still looking
for a home. Those with severe ventricular enlargement asso-
ciated with left anterior descending distribution wall motion
abnormalities, as in Dor and colleagues’ series,3 appear to
benefit from large reductions in ventricular size with SVR.
Apical viability or not, those with modestly enlarged ventri-
cles do not gain any survival benefit from SVR. Like fine
china, this procedure should be stored safely in the closet
and only brought out on special occasions.
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